Haemate P (Human Coagulation Factor Viii, Human Von Willebrand Factor)

Q: What is the mechanism of action of Haemate P?

Haemate P provides exogenous human factor VIII and von Willebrand factor, replacing deficient clotting proteins and restoring normal thrombin generation and platelet adhesion.

Q: For which types of hemophilia is Haemate P indicated?

Haemate P is indicated for hemophilia A, both with and without factor VIII inhibitors, as well as for von Willebrand disease type 3.

Q: How is Haemate P administered to patients?

The product is supplied as a lyophilized powder that is reconstituted and given by intravenous infusion under medical supervision.

Q: Can Haemate P be used in patients who have developed inhibitors to factor VIII?

Haemate P may be used in patients with inhibitors, but efficacy can be reduced; clinicians should monitor inhibitor titers and consider adjunctive therapies.

Q: What are the most common adverse reactions associated with Haemate P?

Common reactions include injection‑site pain or erythema, mild headache, low‑grade fever, nausea or vomiting, and minor skin rash or itching.

Q: How should clinicians monitor for the development of inhibitors when using Haemate P?

Regular Bethesda assay testing is recommended to detect neutralizing antibodies against factor VIII, especially after initial exposure or changes in dosing.

Q: Is Haemate P suitable for surgical prophylaxis in hemophilia A patients?

Yes, Haemate P is used for peri‑operative prophylaxis to maintain adequate factor levels and reduce bleeding risk during surgery.

Q: What precautions should be taken before starting Haemate P therapy?

Clinicians should review allergy history, assess renal and hepatic function, evaluate thrombotic risk, and ensure proper aseptic preparation of the infusion.

Q: Are there any known drug interactions with antifibrinolytic agents and Haemate P?

Antifibrinolytics such as tranexamic acid can be co‑administered but may increase clot stability; patients should be monitored for signs of thrombosis.

Q: How does Haemate P differ from other factor VIII concentrates on the market?

Haemate P contains both factor VIII and von Willebrand factor in a single preparation, providing combined replacement for patients with dual deficiencies.

Haemate P is a lyophilized powder for solution for injection that contains human coagulation factor VIII and human von Willebrand factor. It is supplied without a specified strength and is administered intravenously under prescription. The product is classified as a coagulation factor replacement and is used in the European market for managing bleeding disorders such as hemophilia A and von Willebrand disease in clinical practice.

Manufacturer / TM Owner

Csl Behring Gmbh

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Haemate P is indicated for several therapeutic situations related to deficient clotting factors.

Treatment of hemophilia A, including patients with and without inhibitors.
Management of von Willebrand disease type 3.
Surgical prophylaxis to prevent bleeding in patients with hemophilia A undergoing invasive procedures.
On-demand treatment of acute bleeding episodes in individuals with factor VIII or von Willebrand factor deficiency.
Long‑term prophylactic therapy to reduce the frequency of spontaneous bleeds in severe hemophilia A.

Side Effects

Adverse reactions reported with Haemate P vary in frequency and severity.

Common

Mild pain, redness, or swelling at the injection site.
Transient headache lasting a few hours.
Low‑grade fever (temperature <38.5 °C) shortly after infusion.
Nausea or occasional vomiting during or after administration.
Minor skin rash or itching without systemic involvement.

Serious

Anaphylactic or severe hypersensitivity reactions requiring emergency treatment.
Development of neutralizing antibodies (inhibitors) against factor VIII, reducing efficacy.
Thromboembolic complications such as deep‑vein thrombosis or pulmonary embolism.
Acute renal impairment linked to infusion‑related events.

Precautions & Warnings

When prescribing Haemate P, clinicians should consider several precautionary measures to ensure safe use.

Assess patient history for prior allergic reactions to plasma‑derived products.
Monitor for the emergence of factor VIII inhibitors, especially in previously untreated patients.
Evaluate renal and hepatic function before initiating therapy and periodically during treatment.
Use caution in patients with a history of thromboembolic disease or cardiovascular risk factors.
Adjust dosing in pediatric patients and in individuals with severe bleeding phenotypes.
Ensure proper aseptic technique during reconstitution and intravenous administration.

Avoid Interactions

Haemate P may interact with other medications or biologics, influencing efficacy or safety.

Avoid

Concurrent use of other plasma‑derived clotting factor concentrates without medical supervision.
Administration with investigational gene‑therapy products targeting factor VIII or von Willebrand factor.
Simultaneous infusion of high‑dose immunoglobulins that could interfere with factor activity assays.

Use with caution

Antifibrinolytic agents (e.g., tranexamic acid) may increase clot stability; monitor for thrombosis.
Immunosuppressive drugs that could affect inhibitor development; observe inhibitor titers.
Concomitant use of anticoagulants (e.g., warfarin, direct oral anticoagulants) may require dose adjustments and close monitoring.

Frequently Asked Questions